Veterinary Medicines

ZIPYRAN TABLETS FOR DOGS

Authorised
This information is not available for this product.
Download as PDF

Product identification

Medicine name:
ZIPYRAN TABLETS FOR DOGS
Zipyran tabletten voor honden
Active substance:
This information is not available for this product.
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
This information is not available for this product.
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • Cardboard box containing 1 blister of 2 tablets
  • Cardboard box containing 2 blisters of 2 tablets
  • Cardboard box containing 1 blister of 4 tablets
  • Cardboard box containing 3 blisters of 2 tablets
  • Cardboard box containing 4 blisters of 2 tablets
  • Cardboard box containing 1 blister of 10 tablets
  • Cardboard box containing 25 blisters of 10 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Calier S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Calier S.A.
  • Beaphar B.V.
  • Beaphar B.V.
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 107534
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0224/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Germany
  • Greece
  • Italy
  • Netherlands
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."